Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324022 | 0.95 | HSP90AA1 (0.42) | DHODHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL10324431 | 0.83 | DYRK1A (0.39) | HTR1ADRD2HTR2A | |
| SCHEMBL10322727 | 0.83 | MERTK (0.52) | — | |
| SCHEMBL10322497 | 0.76 | POLB (0.50) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10446540 | 0.74 | DYRK1A (0.72) | — | |
| SCHEMBL10323627 | 0.72 | DYRK1A (0.57) | — | |
| SCHEMBL10323036 | 0.71 | DYRK1A (0.56) | — | |
| SCHEMBL4763435 | 0.71 | GAA (0.49) | — | |
| SCHEMBL10324008 | 0.70 | DYRK1A (0.47) | — | |
| SCHEMBL21709940 | 0.69 | USP2 (0.59) | EPHX2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DHODH 61/4885EPHX2 2147/4885PRKAB2 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.